8 completed, 1 terminated, 1 unknown. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Stage III Melanoma: new trials by email Literature Review of Stage III Melanoma trials Research Report on Stage III Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors TBX-3400 - Stage III Melanoma, Stage IV Melanoma | Phase 1 | Unknown | Taiga Biotechnologies, Inc. | 72 | 2019-06-02 | 2022-05-03 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 26 | 2017-10-31 | 2024-10-01 |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma IMP321 (eftilagimod alpha), Pembrolizumab - Stage IV Melanoma, Stage III Melanoma | Phase 1 | Completed | Immutep Australia Pty. Ltd. | 24 | 2016-04-01 | 2019-12-18 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 69 | 2006-04-01 | 2014-04-10 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery recombinant interferon alfa-2b, amifostine/azacitidine - Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2005-07-01 | 2013-05-03 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-07-01 | 2013-04-10 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers imatinib mesylate, bevacizumab, pharmacological study - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2003-10-01 | 2018-06-20 |
| Decitabine in Treating Patients With Advanced Solid Tumors decitabine, pharmacological study, laboratory biomarker analysis - Male Breast Cancer, Recurrent Bladder Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2001-12-01 | 2013-02-07 |
Melanoma (10) · Breast Neoplasms (2) · Breast Neoplasms, Male (2) · Carcinoma, Renal Cell (2) · Carcinoma, Ovarian Epithelial (1) · Colonic Neoplasms (1) · Esthesioneuroblastoma, Olfactory (1) · Prostatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Neuroendocrine Tumors (10) · Nevi and Melanomas (10) · Skin Diseases (10) · Skin Neoplasms (10) · Skin and Connective Tissue Diseases (10) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Urogenital Diseases (3)
pembrolizumab (3) · 1-methyltryptophan (1) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · Amifostine (1) · Azacitidine (1) · Bevacizumab (1) · Biopsy (1) · Decitabine (1) · Imatinib Mesylate (1) · Immunohistochemistry (1) · Interleukin-2 (1) · Introns (1) · Ipilimumab (1) · Nivolumab (1) · Polymerase Chain Reaction (1)
National Cancer Institute (NCI) (5) · Fred Hutchinson Cancer Center (1) · Immutep Australia Pty. Ltd. (1) · NewLink Genetics Corporation (1) · Taiga Biotechnologies, Inc. (1) · University of Colorado, Denver (1)
United States (9) · Australia (1)
David Solit (1) · Jeffrey Weber (1) · Keith Flaherty (1) · Kevin Kim (1) · Mario Sznol (1) · Martin McCarter, MD (1) · Sylvia Lee (1)
K12CA076930 (1), N01CM62202 (1), P30CA016672 (1), R21CA137647 (1), U01CA062505 (1), U01CA069856 (1)